NYSE$CHE

Chemed Corp · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Chemed's Q2 2021 performance was reported, with increased revenue and adjusted EPS, but decreased GAAP EPS due to declines in the VITAS segment.

Chemed Corporation reported a 6.0% increase in revenue to $532 million for Q2 2021. GAAP EPS decreased by 29.9% to $3.51, while adjusted EPS increased by 4.3% to $4.60. The VITAS segment experienced declines in net patient revenue and ADC, while the Roto-Rooter segment saw significant revenue growth.

  • Consolidated revenue increased by 6.0% to $532 million.
  • GAAP diluted EPS decreased by 29.9% to $3.51.
  • Adjusted diluted EPS increased by 4.3% to $4.60.
  • Roto-Rooter revenue increased by 26.1% to $220 million.

Headline financials

Total Revenue

$532M

Previous: $502M+6.0%
EPS (adj)

$4.60

Previous: $4.41+4.3%
Average Daily Census

18.0K

Previous: 19.2K-6.3%
VITAS Admissions

16.8K

Previous: 16.8K+0.1%
Capital Expenditures

-$33.6M

Previous: -$32.3M-4.2%
Free Cash Flow

$22.9M

Previous: $49.9M-54.0%
Net Income

$56.5M

Previous: $82.1M-31.2%
Operating Income

$71.7M

Previous: $92.8M-22.7%
Gross Profit

$182M

Previous: $150M+21.1%
Cash & Equivalents

$92M

Previous: $20.4M+351.5%
Total Assets

$1.38B

Previous: $1.29B+7.2%

Revenue & EPS history

Chemed · Revenue · Quarterly

$532M

Q2 2021+6%vs Q2 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Chemed · $532M total across 2 segments · Q2 2021

  • VITAS Healthcare
    $312M-4.6%
  • Roto-Rooter
    $220M+25.7%

Forward guidance

Chemed increased its full-year 2021 adjusted earnings per diluted share guidance to a range of $18.20 to $18.50, compared to the initial guidance of $17.00 to $17.50.

Tailwinds

  • VITAS 2021 revenue, prior to Medicare Cap, is estimated to decline approximately 4.5% when compared to the prior year.
  • Average Daily Census in 2021 is estimated to decline approximately 5.0%.
  • Full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 18.3%.
  • Roto-Rooter is forecasted to achieve full-year 2021 revenue growth of 15.0% to 15.5%.
  • Roto-Rooter’s Adjusted EBITDA margin for 2021 is estimated to be between 28% to 29%.

Headwinds

  • COVID-19 pandemic continues to disrupt healthcare system and general economy.
  • Future rules, regulations and government mandates could materially impact the company’s ability to achieve this guidance.
  • Reduced occupancy in senior housing has had a corresponding reduction in VITAS nursing home admissions.
  • VITAS 2021 revenue, prior to Medicare Cap, is estimated to decline approximately 4.5% when compared to the prior year.
  • Average Daily Census in 2021 is estimated to decline approximately 5.0%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.7%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+2.1%

Avg return

30 days after

53%

36 / 68 earnings

Positive

+13.0%

Q3 2015

Best reaction

-14.8%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-0.1%+4.0%
Q4 2025-14.8%-9.1%-21.0%
Q3 2025+6.0%+0.4%+0.1%
Q1 2025-6.6%-1.8%-2.7%
Q4 2024+7.4%+7.7%+11.0%
Q3 2024-12.0%-12.7%-6.2%
Q2 2024-0.1%+2.4%+5.7%
Q1 2024-7.0%-8.1%-9.9%
Q4 2023+5.1%+2.6%+7.3%
Q3 2023+9.3%+10.9%+14.4%
Q2 2023-8.1%-8.0%-10.8%
Q1 2023-3.7%-2.2%-4.1%
Q4 2022+3.3%+1.7%+1.9%
Q3 2022+3.2%+4.1%+12.6%
Q2 2022-6.8%-9.2%-8.3%
Q1 2022-1.4%-1.0%+0.8%
Q4 2021+5.1%+5.8%+3.8%
Q3 2021+9.2%+9.0%+9.4%
Q2 2021-4.4%-0.4%-2.4%
Q1 2021+1.5%+2.3%+6.1%
Q4 2020-0.8%-6.7%-3.9%
Q3 2020+1.2%+3.5%+0.2%
Q2 2020+9.0%+10.3%+12.2%
Q1 2020-3.9%-6.5%+5.6%
Q4 2019+3.2%-1.2%-23.1%
Q3 2019-1.7%+0.6%+5.9%
Q2 2019+3.7%+8.1%+13.9%
Q1 2019-0.6%+0.7%+0.3%
Q4 2018+1.3%+2.8%+1.9%
Q3 2018+6.2%+6.6%+7.6%
Q2 2018+0.4%-2.5%+0.1%
Q1 2018+3.0%+3.3%+13.4%
Q4 2017+2.4%+2.1%+12.9%
Q3 2017+9.1%+5.0%+12.7%
Q2 2017-1.1%-2.3%-6.3%
Q1 2017+10.0%+9.4%+9.0%
Q4 2016+1.9%+2.0%+9.1%
Q3 2016-0.3%+1.8%+6.3%
Q2 2016+5.0%+3.0%-7.9%
Q1 2016-6.7%
Q4 2015-5.6%
Q3 2015+13.0%
Q2 2015+5.1%
Q1 2015-4.7%
Q4 2014+7.5%
Q3 2014-1.2%
Q2 2014+4.3%
Q1 2014-3.3%
Q4 2013+10.5%
Q3 2013-5.2%
Q2 2013-7.3%
Q1 2013+3.4%
Q4 2012+4.9%
Q3 2012-2.0%
Q2 2012+5.1%
Q1 2012+2.9%
Q4 2011+0.0%
Q3 2011+1.5%
Q2 2011-5.8%
Q1 2010-2.6%
Q1 2011+1.8%
Q4 2008-1.6%
Q4 2010-1.6%
Q3 2009+1.4%
Q3 2010+1.4%
Q2 2010-0.9%
Q2 2009-0.9%
Q4 2009-0.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro